Deambulatory Epidural During the Labour

NCT ID: NCT02264834

Last Updated: 2018-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-01

Study Completion Date

2018-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assess the impact of instrumentation and caesarean related to dyskinesia by reducing the concentration of local anesthetic and therefore the motor block.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective, randomized and double-blind study performed on primiparous parturient divided into two distinct groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

First Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL

Group Type ACTIVE_COMPARATOR

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

Intervention Type DRUG

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

Lumbar epidural analgesia

Intervention Type PROCEDURE

Introduction of a catheter in lumbar epidural space

Ambulatory group

Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL

Group Type EXPERIMENTAL

Levobupivacaine 0.07% + Sufentanil 0.3µg/ml

Intervention Type DRUG

Levobupivacaine 0.07% + Sufentanil 0.3µg/ml

Lumbar epidural analgesia

Intervention Type PROCEDURE

Introduction of a catheter in lumbar epidural space

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

Intervention Type DRUG

Levobupivacaine 0.07% + Sufentanil 0.3µg/ml

Levobupivacaine 0.07% + Sufentanil 0.3µg/ml

Intervention Type DRUG

Lumbar epidural analgesia

Introduction of a catheter in lumbar epidural space

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

control group ambulatory group labor analgesia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Free written consent.
* ASA I or II,
* Primipara, unique and pregnancy over 36 weeks fetus in cephalic, cervical dilation between 3-6 cm
* VAS\> 30 mm
* No contraindications to peridural

Exclusion Criteria

* Twin pregnancy, less than 36 weeks and 42 weeks
* Fetus in breech position
* Analgesia and sedation within 6h
* Contraindications to peridural
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr Madeleine Wilwerth

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Madeleine Wilwerth

primary investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Vanderlinden

Role: STUDY_DIRECTOR

CHUB

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHUB

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PDB001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.